Sign in →

Test Code AMPAS Amphetamine Panel, Serum


Ordering Guidance


This test should only be ordered by healthcare professionals to monitor patients who have been prescribed amphetamines or identify misuse/abuse.



Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Red top (Serum gel/SST are not acceptable)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL Serum

Collection Instructions: Within 2 hours of collection, centrifuge and aliquot serum into a plastic vial.


Useful For

Confirming drug exposure involving amphetamine-like stimulants such as methamphetamine, amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxyethylamphetamine (MDEA)

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

Amphetamine Panel, S

Specimen Type

Serum Red

Specimen Minimum Volume

Serum: 0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  15 days

Reference Values

Therapeutic range and metabolite information (as applicable):

Methamphetamine: 10-50 ng/mL

 

Amphetamine: 20-30 ng/mL

Amphetamine is a separate prescribable drug as well as the metabolite of methamphetamine.

 

3,4-methylenedioxymethamphetamine (MDMA): Not Applicable

3,4-methylenedioxyamphetamine (MDA): Not Applicable

3,4-methylenedioxyethylamphetamine (MDEA): Not Applicable

MDA is a separate drug and also a metabolite of MDEA and MDMA.

 

Cutoff concentrations:

Methamphetamine: 5.0 ng/mL

Amphetamine: 5.0 ng/mL

MDMA: 5.0 ng/mL

MDA: 5.0 ng/mL

MDEA: 5.0 ng/mL

Interpretation

Clinically, the presence of amphetamines in serum can be used to verify adherence or compliance and discourage drug misuse, abuse, and diversion.

Clinical Reference

1. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. J Appl Lab Med. 2018;2(4):489-526. doi:10.1373/jalm.2017.023341

2. Langman LJ, Bechtel LK, Holstege CP. Chapter 43: Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham C-AD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43

3. Baselt RC. Disposition of Toxic Drugs and Chemical in Man. 12th ed. Biomedical Publications; 2020

4. Milone MC, Shaw LM. Chapter 42: Therapeutic Drugs and Their Management. In: Rifai N, Chiu RWK, Young I, Burnham C-AD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 42

Day(s) Performed

Tuesday

Report Available

2 to 9 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

G0480

80324 (if appropriate for select payers)

80359 (if appropriate for select payers)

Clinical Toxicology CPT Code Client Guidance

LOINC Code Information

Test ID Test Order Name Order LOINC Value
AMPAS Amphetamine Panel, S In Process

 

Result ID Test Result Name Result LOINC Value
623599 Methamphetamine 3778-8
623600 Amphetamine 30112-7
623601 Methylenedioxymethamphetamine-MDMA 18356-6
623602 Methylenedioxyamphetamine-MDA 59837-5
623603 Methylenedioxyethylamphetamine-MDEA 33016-7